We investigated the serial change in body weight during neoadjuvant chemotherapy (NAC) and the presence and degree of lymphedema (LE) using a telephone questionnaire assessment of 406 in breast cancer. The increase in body weight during NAC was significant after the second cycle of taxane. The body weight change was more significant in the LE group. Introduction: The aim of our study was to analyze the risk of lymphedema (LE) according to the clinicopathologic factors and to investigate the serial change in body weight during neoadjuvant anthracycline plus cyclophosphamide followed by taxane and its correlation with the incidence of LE. Patients and Methods: We performed a retrospective 2-center study of 406 patients who had undergone neoadjuvant chemotherapy (NAC) followed by surgery from 2007 to 2014. The regimen included 4 cycles of anthracycline plus cyclophosphamide, followed by 4 cycles of taxane. We investigated the presence and degree of LE using a telephone questionnaire assessment. Weight changes were calculated at each cycle of NAC, and the baseline and preoperative body weights were used to calculate the rate of change to account for the change in weight before and after NAC. Results: Of the 406 patients, 270 answered the questionnaires, of whom 97 (35.9%) experienced LE. The increase in body weight was significant during the 4 cycles of taxane, but the change in weight was not significant during the 4 cycles of anthracycline plus cyclophosphamide. The change in body weight was most significant just after the fourth cycle of taxane (P < .001). The body mass index (BMI) was an independent factor of LE occurrence on multivariate analysis. However, the change in body weight was not a significant factor for the incidence of LE. Conclusion: Because a BMI ! 25 kg/m 2 was an independent factor of LE occurrence on multivariate analysis, patients with a preoperative BMI ! 25 kg/m 2 should be closely monitored for LE given their increased risk, and monitoring and education should be initiated before surgery and continued throughout the course of NAC.
Introduction
Breast cancer-related lymphedema (LE) is associated with significant physical and psychosocial consequences, which have been well-reported. 1, 2 The incidence of LE after breast cancer treatment has been reported to vary from < 5% to > 60% depending on a clinical history of axillary lymph node (ALN) dissection (ALND) S.P. and J.E.L. contributed equally to this work as first authors. J.Y. and E.J.Y. contributed equally to this work as corresponding authors.
and/or radiotherapy (RT). 3 Recent data from a meta-analysis have suggested that > 1 in 5 patients who survive breast cancer will develop LE. 4 It is believed that the combination of physical alterations of the secondary and tertiary lymphatics resulting from surgery, RT to the regional lymphatics, and the chemotherapy agents commonly used to treat breast cancer can further exacerbate this inflammatory response. 5 Chemotherapy using anthracycline or taxane has been suggested to increase the risk of LE owing to generalized swelling. 6 Neoadjuvant (preoperative or primary) systemic chemotherapy has been the longstanding treatment of choice for patients with locally advanced breast cancer. 7 Neoadjuvant chemotherapy (NAC), followed by ALND, is widely used in the treatment of advanced breast cancer. 8 Moreover, RT is usually administered according to the clinical stage before NAC; thus, the risk of LE is likely to increase. A study by the National Surgical Adjuvant Breast and Bowel Project B-27 trials demonstrated that the use of neoadjuvant doxorubicin plus cyclophosphamide, followed by docetaxel, has become the standard of care for lymph node-positive patients. 9 Despite the increasing use of NAC for breast cancer, the relationship between the body weight change and the development of LE needs to be more clearly established.
The first aim of our study was to analyze the risks of LE according to the clinicopathologic factors. The second was to investigate the rate of body weight change at every cycle of NAC using the anthracycline, cyclophosphamide plus taxane regimen and the correlation of the body weight change with the incidence of LE.
Patients and Methods
We performed a retrospective 2-center study of 406 patients with advanced breast cancer who had undergone NAC followed by definitive surgery with ALND from January 2007 to December 2014 at Samsung Medical Center and Seoul National University Bundang Hospital. Patients with bilateral breast cancer, inflammatory breast cancer, or distant metastasis and patients who had a previous or concurrent second malignancy were excluded. The regimen included 4 cycles of anthracycline plus cyclophosphamide, followed by 4 cycles of taxane. The body weight during every cycle of NAC was monitored. Surgery involving either total mastectomy or breast-conserving surgery with ALND was performed within 3 to 4 weeks after NAC, unless evidence of disease progression was found. Standard level 1 and 2 ALND was performed, with or without sentinel lymph node biopsy, in all patients. Patients underwent ipsilateral breast (or chest wall) RT with or without supraclavicular RT in accordance with our institutional policy. Planning computed tomography scans were performed, and RT was performed using conventional techniques.
Diagnosis of Breast Cancer-related LE
We investigated the presence and degree of LE by telephone questionnaire assessment using a self-reporting system. 10 We asked patients whether they had noticed any difference in both hands, lower arms, or upper arms and any difference in size between the 2 limbs during the previous 3 months. To assess the degree of LE, we Risk Factors Affecting Breast Cancer-related LE then asked whether the difference in the size of limbs was (1) very slight (ie, the patient was the only person who would notice the difference; grade 1); (2) noticeable to people who know the patient well but not to strangers (grade 2); or (3) very noticeable (grade 3). We compared the incidence of LE between the self-reported system and measured grades in the clinic at a single center and evaluated the correlation between the 2 factors.
Weight Change Evaluation
We measured the initial body weight at baseline (at the first cycle of AC) and at cycle of NAC (4 cycles of anthracycline plus cyclophosphamide, followed by 4 cycles of taxane). We also measured the preoperative body weight just before surgery. We evaluated the correlation between the changes in body weight before and after NAC and the incidence of LE. We also investigated the incidence of LE stratified by the change in body weight. The weight change variables were calculated at each follow-up weight measurement, and the baseline and preoperative body weight were used to calculate the rate of change to account for the change in weight before and after NAC.
Statistical Analysis
Repeated analysis of variance was used to evaluate the body weight changes according to the 8 divisions of the duration between the LE and non-LE groups. The paired t test was used to evaluate the change in body weight during NAC. Logistic regression models were used to evaluate the univariate and multivariate risk factors associated with the development of LE. Also, the body mass index (BMI), ypT classification, ypN classification, ypStage, hormone receptor status, surgery type, number of removed ALNs and level of dissection of ALND were measured from the date of surgery. General linear regression analysis was used to evaluate the risk factors associated with the LE grade. Variables found to be significant or borderline significant (P < .2) on univariate analysis were selected for multivariate analysis. The statistical tests were 2-sided, and statistical significance was defined at P < .05. SAS, version 9.4 (SAS Institute, Cary, NC), was used for the c 2 test, paired t test, and logistic regression analysis. We used SPSS, version 22 (IBM Corp, Armonk, NY), for repeated analysis of variance.
The institutional review boards of the Samsung Medical Center (approval no. 2016-08-010) and Seoul National University Bundang Hospital (approval no. B-1607-353-106) approved the present study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Results
The patient and treatment characteristics are summarized in Table 1 . The mean patient age at surgery was 48.5 years (range, 22-79 years), and the median follow-up period was 54 months 
LE Incidence and Grade
Of the 406 patients, 270 completed the questionnaires, 97 of whom (35.9%) developed LE. Fifty-three patients (54.6%) reported having grade 1 LE, 30 (30.9%) reported having grade 2, and 14 patients (14.4%) reported having grade 3 LE. Breast-conserving surgery was performed in 131 patients (48.5%) and mastectomy in 139 patients (51.5%). We measured the grade of LE for 57 of 185 patients at a single center. Of these 57 patients, LE was diagnosed in 37, 24 of whom had LE of grade > 2. When we compared the incidence of LE between the self-reported system and LE grades measured in the clinic, the incidence of LE from the self-reported system correlated with grade > 2 in the clinic at a single center (k ¼ 0.414; P < .001).
Change in Body Weight During NAC
The increase in body weight during NAC was significant after the second cycle of taxane in the LE and non-LE groups both (taxane cycle 2 to taxane cycle 3, P ¼ .04; taxane cycle 3 to taxane cycle 4, P ¼ .24; and taxane cycle 4 to surgery, P ¼ .01). We also confirmed that the body weight change was more significant in the LE group than in the non-LE group (P < .001; Figure 1 ). The changes in body weight were the most significant just after the fourth cycle of taxane ( Table 2 ). The mean BMI was 22.4 AE 3.35 kg/m 2 . The change in body weight correlated negatively with the BMI (P ¼ .016; Figure 2 ).
Risk Factors That Correlated With LE Occurrence and Grade
The results of the univariate analysis of the factors associated with the development of LE are listed in Table 3 . The BMI (P ¼ .012), number of dissected ALNs (P ¼ .045), and level of ALND (P ¼ .04) correlated significantly with an increased rate of LE development. The ypT stage (P ¼ .063), ypN stage (P ¼ .054), and RT fields (P ¼ .125) showed borderline significance with LE development. Multivariate analysis showed that a BMI ! 25 kg/m 2 (odds ratio, 1.722; 95% confidence interval, 0.802-3.695; P ¼ .077) was an independent factor for the development of LE.
The results of the univariate analysis of factors associated with the grade of LE are listed in Table 4 . The ypT stage (P ¼ .085), hormone receptor status (P ¼ .134), and number of dissected ALNs (P ¼ .021) correlated with the LE grade. Multivariate analysis showed that ypT stage (P ¼ .005) and hormone receptor status (P ¼ .001) were independent factors for the grade of LE.
Discussion
In the present study, 97 of 207 patients (35.9%) experienced LE. The increase in body weight during NAC was significant after the second NAC taxane cycle, and the change in body weight was more significant in the LE group than in the non-LE group (P < .001; Figure 1 ). The changes in body weight were the most significant just after the fourth taxane cycle. The change in body weight correlated negatively with the BMI. On univariate analysis, the BMI, number of dissected ALNs, and level of ALND correlated significantly with an increased rate of LE development. The BMI was an independent factor of LE occurrence on multivariate analysis. However, the change in body weight was not a significant factor for the development of LE. The ypT stage and hormone receptor status were independent factors for the grade of LE.
In the present study, the change in body weight correlated negatively with the BMI. In a previous study, obesity was more common in women who had gained weight between the diagnosis of breast cancer and 6 months after the diagnosis. 11 Some studies found no difference in weight gain between patients with a BMI of ! 25 kg/m 2 and a BMI < 25 kg/m 2 . 12 In a study of weight changes after diagnosis and the prognosis among women with earlystage breast cancer, of the women with a BMI < 30 kg/m 2 , 38.9% had gained ! 5% of their body weight compared with 25.9% who had gained the same amount among women with a BMI of ! 30 kg/m 2 , 13 consistent with the results from our study. However, our results should not be generalized to other conditions, because the mean BMI in the present study was relatively lower than that in other studies, and patients with a BMI of ! 25 kg/m 2 constituted 21.9% of the study population. In the present study, an increase in body weight was most significant after the fourth cycle of taxane. However, the change in body weight was not a significant factor for the development of LE. Systemic chemotherapy increases the incidence of LE. A meta-analysis showed that chemotherapy is a risk factor for LE development. 4 A previous study demonstrated that taxane-based chemotherapy was a significant risk factor for LE development 9 months after surgery. 14 The mechanism underlying taxane use and LE development is unknown. Taxane causes generalized edema by increasing the interstitial extracellular fluid volume. 15, 16 However, the specific factors that affect the development of LE remain unclear. Some studies have investigated the effect of BMI and obesity on the development of LE. 17, 18 Other studies have reported that weight gain alone is a risk factor for LE. 19, 20 It has even been proposed that large, postoperative fluctuations in weight significantly increase a patient's risk of developing LE. 21 The present study's results highlight the changes in body weight over time during NAC that included taxane. Several studies have shown that patients who received NAC experienced more LE events than did an adjuvant chemotherapy (ACT) group. However, no study has compared the development of LE after NAC versus after ACT. 22, 23 A recent study showed that patients receiving NAC experienced more persistent LE compared with those receiving ACT, regardless of stage. 24 Several points should be considered in explaining why the incidence of LE was high in the present study. All the patients had undergone NAC and surgery with ALND, followed by whole breast or chest wall RT with or without supraclavicular RT, all of which are considered significant risk factors for LE development. 25, 26 Another point to consider is that these patients might have undergone more aggressive axillary surgery after NAC because they all initially had had clinically nodepositive breast cancer. The proportion of patients with > 15 dissected ALNs in the present study was 173 (64.1%). The present study had certain limitations. First, we used a selfreporting system rather than an objective assessment for the diagnosis of LE. However, the use of a telephone questionnaire led to agreement with health care professionals' judgment about LE in a previous study. 10 Moreover, we found that the incidence of LE from the self-reported system correlated with grade > 2 in the clinic at a single center when we compared the 2 factors. Therefore, patient selfperception was important to properly detect LE. Second, in our retrospective analysis, patient-related factors (intravenous drug injection, blood sampling, blood pressure measurement using the arm of the affected side, and excessive hand use) could not be tested or included in the risk groups, because we did not use questionnaires that 
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Conclusion
The changes in body weight were most significant just after the fourth cycle of taxane during NAC with the anthracycline plus cyclophosphamide, followed by taxane, regimen. However, an increase in body weight was not an independent risk factor for the development of LE. The BMI correlated negatively with the change in body weight. Because a BMI ! 25 kg/m 2 was an independent factor for LE occurrence on multivariate analysis, patients with a preoperative BMI ! 25 kg/m 2 should be closely monitored for LE owing to their increased risk. Also, monitoring and education should be initiated before surgery and continued throughout the NAC course.
